Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 113 (6), 807-814
- https://doi.org/10.1007/s12185-021-03115-9
Abstract
It is unknown whether adding stanozolol to decitabine for maintenance can further improve progression-free survival (PFS) and overall survival (OS) after effective decitabine treatment in patients with high-risk myelodysplastic syndrome (MDS). Patients newly diagnosed with high-risk MDS who achieved at least partial remission after 4 cycles of decitabine (20 mg/m2 days 1–5) were selected. In total, 62 patients (median age 66 years) were enrolled, of whom 21 were treated with stanozolol and decitabine for maintenance, and 41 were treated with decitabine alone. The median number of cycles for maintenance treatment was 6 (2–11) and 5 (2–12) for the stanozolol and control groups, respectively (p > 0.05). PFS in the stanozolol group was significantly longer than in the control group (15.0 vs 9.0 months, hazard ratio [HR] = 0.35, 95%CI: 0.19–0.63, p = 0.0005), whereas OS was not significantly prolonged in the stanozolol group (21.0 vs 15.0 months, HR = 0.73, 95%CI: 0.39–1.37, p = 0.33). The proportion of patients with severe neutropenia during maintenance treatment in the stanozolol group was lower than in the control group (76.2% vs 95.1%, p = 0.039). In conclusion, adding stanozolol to decitabine after effective decitabine treatment can prolong PFS and reduce the severity of neutropenia for patients with high-risk MDS.Keywords
Funding Information
- National Natural Science Foundation of China (81970116, 81770118, 81170472)
- National Natural Science Foundation of China (81970116, 81770118, 81170472)
- Natural Science Foundation of Tianjin China (16JCZDJC35300)
- Key Technology Research and Development Program of Tianjin China (18ZXDBSY00140)
- Beijing Natural Science Foundation (7192168)
- the Chinese Academy of Medical Sciences (CAMS) innovation for medical sciences (2016-I2M-3-004)
This publication has 33 references indexed in Scilit:
- The progression risk factors of children with transfusion-independent non-severe aplastic anemiaInternational Journal of Hematology, 2013
- Telomere length in myelodysplastic syndromesLeukemia & Lymphoma, 2011
- Telomere maintenance and human bone marrow failureBlood, 2008
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndromeAmerican Journal of Hematology, 2002
- Effects of two sex steroids (17β estradiol and testosterone) on proliferation and clonal growth of the human monoblastic leukemia cell line, U937Leukemia Research, 1998
- Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 casesBritish Journal of Haematology, 1994
- Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemiaLeukemia Research, 1981